Seeking Alpha
View as an RSS Feed

Dan Lukehart  

View Dan Lukehart's Comments BY TICKER:
Latest  |  Highest rated
  • Whole Genome Sequencing: Fueling Medicine's Next Revolution [View article]
    Update: Nova did a cool program about this same thing on March 28th. You can watch it online here:

    http://to.pbs.org/HDwEOM
    Mar 31, 2012. 02:39 PM | Likes Like |Link to Comment
  • Interesting Reaction To Oncothyreon's Share Offering [View article]
    Jay, I sincerely wish you the best with your battle with lung cancer. one of the reasons I invest in biotech is to help people in your situation in some small way.

    According to clinicaltrials.gov "This study is ongoing, but not recruiting participants."

    Can you offer any explanation for why it says it is closed but you are under consideration to be admitted?
    Mar 30, 2012. 06:44 PM | Likes Like |Link to Comment
  • Interesting Reaction To Oncothyreon's Share Offering [View article]
    I am not saying I am right - nor did I claim with certainty that it will succeed. Of course it can fail to be approved or show significant benefit to survival. Like anything in startup biotech, it is speculation based on limited data. Saying one knows it will be approved or denied with certainty is crazy. I am just an individual investor who shared in a blog why I invested in a stock.
    Mar 30, 2012. 12:23 PM | Likes Like |Link to Comment
  • Interesting Reaction To Oncothyreon's Share Offering [View article]
    "Primary Outcome Measures:
    To compare survival duration of all randomized subjects by treatment arm [ Time Frame: Interim analysis at 353 + 529 events (deaths); Final analysis at 705 events (deaths) ] [ Designated as safety issue: No ]"

    According to clinicaltrials.gov, the conclusion of the trial is only determined when it reaches 705 deaths. Placebo group living longer would be bad for any drugs chances, but it does not effect the end date for the trial. If the drug appeared to offer no (or negative) benefit relitive to placebo at the interim look, it would have been stopped.
    Mar 30, 2012. 12:15 PM | Likes Like |Link to Comment
  • Future Trends In RNAi Drug Delivery [View article]
    Thank you for you addition. I mixed up the two for some reason. Never the less, SC may become a trend.
    Mar 28, 2012. 05:30 PM | Likes Like |Link to Comment
  • Future Trends In RNAi Drug Delivery [View article]
    Update: Tekmira halted its SC PLK1 trial shortly after this article was written. Said it didnt need SC because it was just to provide human proof of concept to drum up interest in RNAi. Said Alnylam already did that and there was no need now. It will focus the money savied on its regular PLK1 trial and other areas.
    Mar 28, 2012. 12:43 PM | Likes Like |Link to Comment
  • Positive FDA Recommendation For Drug Good News For Tekmira [View article]
    Thank you Chris.

    With our new information, I think it is better for both TLON and TKMR. TLON's milestone payment wont break the bank, but TKMR stands to profit up to an additional 18mil.
    Mar 24, 2012. 03:25 PM | Likes Like |Link to Comment
  • Positive FDA Recommendation For Drug Good News For Tekmira [View article]
    Thank you for the comments Craig! I'm guessing we can fill in the blanks of part 3.1.1 of the 2nd amendment with 1,000,000 as the milestone payment. Can you elaborate more on the royalty payments specific to Marqibo in 3.1.2? There are several items omitted that make the exact financial benefit hard to determine.

    http://bit.ly/GS5OU7

    Congrats on the 7-4 by the way!
    Mar 23, 2012. 03:13 PM | Likes Like |Link to Comment
  • Positive FDA Recommendation For Drug Good News For Tekmira [View article]
    "Talon is developing targeted chemotherapy products under a legacy license agreement entered into in May 2006. Marqibo® (Optisomal Vincristine), Alocrest TM(formerly INX-0125, Optisomal Vinorelbine) and Brakiva TM(formerly INX-0076, Optisomal Topotecan), products originally developed by us, have been exclusively licensed to Talon. Talon has agreed to pay us milestones and royalties and is responsible for all future development and future expenses. In May 2009, the license agreement with Talon was amended to decrease the size of near-term milestone payments and increase the size of long-term milestone payments. On September 20, 2010, the license agreement with Talon was amended a second time such that Talon paid $5.9 million (US$5.75 million) in consideration for reducing certain future payments associated with the product candidates. The payment of $5.9 million (US$5.75 million) from Talon has been paid to certain of our contingent creditors in full settlement of a contingent obligation.We are now eligible to receive milestone payments from Talon of up to US$19.0 million upon achievement of further development and regulatory milestones and we are also eligible to receive single digit royalties on product sales. The milestone payments can be made in common shares of Talon. If Talon sublicenses any of the product candidates, Tekmira is eligible to receive a percentage of any upfront fees or milestone payments received by Talon."
    Mar 23, 2012. 10:44 AM | Likes Like |Link to Comment
  • Positive FDA Recommendation For Drug Good News For Tekmira [View article]
    An update:

    According to TKMR, it is actually entitled to receive 19 million in total milestones. It is payable in TLON common stock. I will likely speak with TKMR CEO late next week and will ask for a breakdown of how the milestones work.
    Mar 23, 2012. 10:34 AM | Likes Like |Link to Comment
  • Positive FDA Recommendation For Drug Good News For Tekmira [View article]
    most likely through a share offering and/or product sales.

    sorry about the article title. SA edited the title and made a mistake in the process
    Mar 22, 2012. 04:00 PM | Likes Like |Link to Comment
  • What Alnylam Doesn't Want You To Know [View article]
    Im 99.99% sure there was JUST a little bit of sarcasm in ddRNAIi's post.
    Mar 17, 2012. 01:28 PM | Likes Like |Link to Comment
  • What Alnylam Doesn't Want You To Know [View article]
    Thank you for your comments mmayne. I don't doubt you guys have the spelling of "patient" in your version of the article, but a whole page search only finds the use of that spelling in the comments section. Id be happy to submit a request to the SA editing team, but I need to identify exactly where it is for them.
    Mar 16, 2012. 12:25 PM | Likes Like |Link to Comment
  • What Alnylam Doesn't Want You To Know [View article]
    Can you point out where please? ill happily submit a request to have it changed with the SA editors. I have no direct control once published.
    Mar 16, 2012. 11:51 AM | Likes Like |Link to Comment
  • Whole Genome Sequencing: Fueling Medicine's Next Revolution [View article]
    Basically, what peluka said. The thing is, while I think outsourcing will be a trend, it might not be ready just yet. We are close, but not yet. There is a huge risk but also a huge reward.

    This sock is heavily shorted. Once the price gets moving downward, it spirals. Any good news will send it sharply upward. I think most people who invest with Complete Genomics (I own a small amount of shares but nothing to write home about) understands the risks with this company. I will do an article that only focuses on GNOM shortly.
    Mar 16, 2012. 12:37 AM | Likes Like |Link to Comment
COMMENTS STATS
23 Comments
2 Likes